Ob/gyns can better identify patients prone to deep vein thrombosis and fetal loss by learning more about this group of disorders.
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
FDA grants Priority Review to flibanserin for treating postmenopausal HSDD
July 24th 2025The FDA has granted Priority Review to expand flibanserin (Addyi; Sprout Pharmaceuticals) use to postmenopausal women, potentially broadening access to treatment for hypoactive sexual desire disorder.
Read More